Pharmaceutical Nitrosamines: A Comprehensive Review of Health Risks, Detection, Mitigation Strategies Supplemented with CYP450 Interactions as Molecular Simulations for Mechanistic Insight into Carcinogenicity
Bibliographic record
Abstract
Nitrosamines, identified as unexpected impurities in several drug substances and drug products, have raised significant concern due to their mutagenic and carcinogenic properties. Extensive research has shown that a majority of nitrosamines are potent carcinogens, affecting various organs in multiple species. This article comprehensively analyzes pharmaceutical nitrosamine impurities, their potential health risks, detection, and mitigation strategies, along with a molecular simulation-based exploration of nitrosamine interaction with CYP450 isoforms. The article also explores the chemistry behind nitrosamine formation, their reactions, and the role of cytochrome P450 enzymes in their metabolism. Detection methods like HPLC, LC-MS, and GC-MS, alongside regulatory guidelines from agencies such as the FDA, EMA, ANVISA, TGA, and Health Canada, are discussed in detail. The review further emphasizes the significance of stringent quality control, comprehensive risk assessment methodologies, and effective risk mitigation strategies to address nitrosamine contamination in pharmaceuticals. Nitrosamine impurities require metabolic transformation into electrophiles, which can readily react with DNA and result in mutagenic or carcinogenic effects. This molecular-level understanding can extensively help explore promising nitrosamine scavengers to minimize the chances of possible health hazards due to nitrosamine exposure. Therefore, the interactions of nitrosamine impurities with CYP450 isoforms are explored to get mechanistic insight into carcinogenicity using molecular docking with Xtra precision, along with molecular dynamics studies. Thus, the review provides a detailed spectrum of nitrosamine impurities in pharmaceuticals, covering their sources, toxicological mechanisms, current regulatory overview, risk assessment, and mitigation strategies to ensure drug safety.
Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.
How this classification was reachedexpand
Full frame machine prediction
Teacher imitationNot calibrated prevalence, not ground truth. Human validation pending. The Gemma side is a direct model label for every work in the frame, read from the title-only record. The Codex side is a classifier learned from the 10,348 direct Codex labels and calibrated to design-weighted sample rates; fields without enough sample support carry no Codex call. Candidate is the union of the two sides; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels.
Distilled classifier scores by category (both heads)
| Category | Codex | Gemma |
|---|---|---|
| Metaresearch | 0.001 | 0.001 |
| Meta-epidemiology (narrow) | 0.001 | 0.001 |
| Meta-epidemiology (broad) | 0.001 | 0.002 |
| Bibliometrics | 0.001 | 0.001 |
| Science and technology studies | 0.000 | 0.000 |
| Scholarly communication | 0.001 | 0.001 |
| Open science | 0.001 | 0.001 |
| Research integrity | 0.001 | 0.001 |
| Insufficient payload (model declined to judge) | 0.003 | 0.001 |
Machine scores (provisional)
The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.
Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.
score_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from itClassification
machine, unvalidatedMachine predicted; a candidate call from one source (direct Gemma or distilled Codex), not a consensus.
How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".